Advertisement

Evaluation of cerebrospinal clonal gene rearrangement in newly diagnosed non-Hodgkin’s lymphoma patients

  • Boaz NachmiasEmail author
  • Veronica Sandler
  • Elena Slyusarevsky
  • Galina Pogrebijski
  • Svetlana Kritchevsky
  • Dina Ben-Yehuda
  • Neta Goldschmidt
  • Moshe E. Gatt
Original Article

Abstract

Overt central nervous system (CNS) involvement in aggressive non-Hodgkin’s lymphoma (NHL) is rare at diagnosis. Much effort is put to identify risk factors for occult CNS involvement, and the risk assessment of CNS relapse. Prophylactic treatment carries risk of adverse events and its efficacy is not clear. Detection of cerebrospinal fluid molecular gene rearrangement (GRR) as a method to detect occult disease has been studied in acute leukemia and primary CNS lymphoma. To date, the capacity of a positive GRR in newly diagnosed NHL patients to predict CNS relapse has not been addressed. We retrospectively studied the prognostic value of GRR in cerebrospinal fluid samples of 148 newly diagnosed patients with high grade NHL. We demonstrate that positive GRR at diagnosis does not affect PFS or OS and did not predict CNS relapse. However, although numbers were small, repeated positive samples (≥ 2) correlated with a higher risk for CNS relapse (p = 0.048), possibly stressing the need for an aggressive preventive approach.

Keywords

Non-Hodgkin lymphoma Gene rearrangement CSF Central nervous system (CNS) 

Notes

Compliance with ethical standards

The retrospective data collection was approved by the local ethics committee in accordance with the Helsinki declaration standards and provided informed consent to participate in the study. All patients gave their informed consent prior to their inclusion in the study.

References

  1. 1.
    Gazzola A, Mannu C, Rossi M, Laginestra MA, Sapienza MR, Fuligni F, Etebari M, Melle F, Sabattini E, Agostinelli C, Bacci F, Sagramoso Sacchetti CA, Pileri SA, Piccaluga PP (2014) The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies. Ther Adv Hematol 5:35–47.  https://doi.org/10.1177/2040620713519729 CrossRefGoogle Scholar
  2. 2.
    Goldschmidt N, Darawshy F, Kleinstern G, Slyusarevsky E, Pogrebijski G, Krichevsky S, Ben-Yehuda D, Gatt ME (2017) The prognostic value of bone marrow involvement at the molecular level in aggressive lymphoma. Leuk Lymphoma 58:45–52.  https://doi.org/10.1080/10428194.2016.1201569 CrossRefGoogle Scholar
  3. 3.
    Ekstein D, Ben-Yehuda D, Slyusarevsky E, Lossos A, Linetsky E, Siegal T (2006) CSF analysis of IgH gene rearrangement in CNS lymphoma: relationship to the disease course. J Neurol Sci 247:39–46.  https://doi.org/10.1016/j.jns.2006.03.012 CrossRefGoogle Scholar
  4. 4.
    Sayed D, Badrawy H, Ali AM, Shaker S (2009) Immunophenotyping and immunoglobulin heavy chain gene rearrangement analysis in cerebrospinal fluid of pediatric patients with acute lymphoblastic leukemia. Leuk Res 33:655–661.  https://doi.org/10.1016/j.leukres.2008.09.033 CrossRefGoogle Scholar
  5. 5.
    Pine SR, Yin C, Matloub YH, Sabaawy HE, Sandoval C, Levendoglu-Tugal O, Ozkaynak MF, Jayabose S (2005) Detection of central nervous system leukemia in children with acute lymphoblastic leukemia by real-time polymerase chain reaction. J Mol Diagn 7:127–132.  https://doi.org/10.1016/S1525-1578(10)60018-9 CrossRefGoogle Scholar
  6. 6.
    Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, Glass B, Scott DW, Gascoyne RD, Connors JM, Ziepert M, Pfreundschuh M, Loeffler M, Savage KJ (2016) CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 34:3150–3156.  https://doi.org/10.1200/JCO.2015.65.6520 CrossRefGoogle Scholar
  7. 7.
    International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329:987–994.  https://doi.org/10.1056/NEJM199309303291402 CrossRefGoogle Scholar
  8. 8.
    Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance, Australasian Leukaemia and Lymphoma Group, Eastern Cooperative Oncology Group, European Mantle Cell Lymphoma Consortium, Italian Lymphoma Foundation, European Organisation for Research, Treatment of Cancer/Dutch Hemato-Oncology Group, Grupo Español de Médula Ósea, German High-Grade Lymphoma Study Group, German Hodgkin's Study Group, Japanese Lymphorra Study Group, Lymphoma Study Association, NCIC Clinical Trials Group, Nordic Lymphoma Study Group, Southwest Oncology Group, United Kingdom National Cancer Research Institute (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059–3067.  https://doi.org/10.1200/JCO.2013.54.8800 CrossRefGoogle Scholar
  9. 9.
    Pongers-Willemse MJ, Seriu T, Stolz F, d'Aniello E, Gameiro P, Pisa P, Gonzalez M, Bartram CR, Panzer-Grümayer ER, Biondi A, San Miguel JF, van Dongen J (1999) Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia 13:110–118CrossRefGoogle Scholar
  10. 10.
    Cheah CY, Herbert KE, O’Rourke K et al (2014) A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. Br J Cancer 111:1072–1079.  https://doi.org/10.1038/bjc.2014.405 CrossRefGoogle Scholar
  11. 11.
    Hegde U (2005) High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 105:496–502.  https://doi.org/10.1182/blood-2004-05-1982 CrossRefGoogle Scholar
  12. 12.
    Benevolo G, Stacchini A, Spina M, Ferreri AJM, Arras M, Bellio L, Botto B, Bulian P, Cantonetti M, Depaoli L, di Renzo N, di Rocco A, Evangelista A, Franceschetti S, Godio L, Mannelli F, Pavone V, Pioltelli P, Vitolo U, Pogliani EM, on behalf of the Fondazione Italiana Linfomi (2012) Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. Blood 120:3222–3228.  https://doi.org/10.1182/blood-2012-04-423095 CrossRefGoogle Scholar
  13. 13.
    Liu L, Cao F, Wang S, Zhou J, Yang G, Wang C (2015) Detection of malignant B lymphocytes by PCR clonality assay using direct lysis of cerebrospinal fluid and low volume specimens. Int J Lab Hematol 37:165–173.  https://doi.org/10.1111/ijlh.12255 CrossRefGoogle Scholar
  14. 14.
    Abramson JS, Hellmann M, Barnes JA, Hammerman P, Toomey C, Takvorian T, Muzikansky A, Hochberg EP (2010) Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer 116:4283–4290.  https://doi.org/10.1002/cncr.25278 CrossRefGoogle Scholar
  15. 15.
    Ferreri AJM, Bruno-Ventre M, Donadoni G, Ponzoni M, Citterio G, Foppoli M, Vignati A, Scarfò L, Sassone M, Govi S, Caligaris-Cappio F (2015) Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. Br J Haematol 168:654–662.  https://doi.org/10.1111/bjh.13194 CrossRefGoogle Scholar
  16. 16.
    Guirguis HR, Cheung MC, Mahrous M, Piliotis E, Berinstein N, Imrie KR, Zhang L, Buckstein R (2012) Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature. Br J Haematol 159:39–49.  https://doi.org/10.1111/j.1365-2141.2012.09247.x CrossRefGoogle Scholar
  17. 17.
    Siegal T, Goldschmidt N (2012) CNS prophylaxis in diffuse large B-cell lymphoma: if, when, how and for whom? Blood Rev 26:97–106.  https://doi.org/10.1016/j.blre.2011.12.001 CrossRefGoogle Scholar
  18. 18.
    Kansara R (2018) Central nervous system prophylaxis strategies in diffuse large B cell lymphoma. Curr Treat Options in Oncol 19(52):52.  https://doi.org/10.1007/s11864-018-0569-2 CrossRefGoogle Scholar
  19. 19.
    Goldschmidt N, Horowitz NA, Hefetz V et al (2019) Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse. Leuk Lymphoma 60:1–9.  https://doi.org/10.1080/10428194.2018.1564823 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Hematology DepartmentHadassah Hebrew University Medical CenterJerusalemIsrael

Personalised recommendations